Medicine and Dentistry
Age
13%
Antibody
16%
Antithrombotic
20%
Assay
66%
Assessment
19%
Association
11%
Bleeding
23%
Bleeding Disorder
17%
Blood
23%
Blood Clotting
9%
Blood Clotting Factor
15%
Blood Clotting Factor 8
20%
Blood Stasis
81%
Cardiovascular Disease
10%
Cells
13%
Coagulation
17%
Collagen
16%
Combination Therapy
35%
COVID-19
20%
D-Dimer
15%
Development
16%
Diagnosis
80%
Diseases
36%
Evaluation Study
9%
Fibrinogen
12%
Haemophilia
10%
Heparin
18%
Heparin-Induced Thrombocytopenia
16%
Inpatient
14%
Laboratory
65%
Laboratory Test
27%
Lupus Anticoagulant
15%
Monitoring
13%
Patient
74%
PFA-100
16%
Phlebothrombosis
10%
Plasma
25%
Platelet
30%
Prothrombin Time
12%
Screening
10%
Therapeutic Procedure
16%
Thrombocyte Aggregation
10%
Thrombocyte Function
26%
Thrombophilia
9%
Thrombosis
48%
Thrombotic Thrombocytopenic Purpura
11%
Vaccine
14%
Venous Thromboembolism
18%
Von Willebrand Disease
85%
Von Willebrand Factor
85%
Biochemistry, Genetics and Molecular Biology
ABO Blood Group System
5%
Activated Protein C Resistance
5%
ADAMTS13
13%
Age
8%
Antibody
10%
Antiphospholipid Antibody
8%
Association
5%
Blood Coagulation Factor
8%
Classification
5%
Coagulation
25%
Coagulation System
5%
Coagulation Testing
7%
Cofactors
5%
Collagen
14%
Consensus
6%
Coronavirinae
5%
D-Dimer
12%
Development
6%
Electric Potential
17%
Experience
5%
Factor VIII
17%
Fibrinogen
14%
Haemophilia
10%
Hematology
5%
Hemostasis
45%
Heparin
19%
Heparin-Induced Thrombocytopenia
10%
Laboratory Test
37%
Lupus Anticoagulant
18%
Mutation
7%
Partial Thromboplastin Time
32%
Platelet
12%
Protein C
12%
Prothrombin Time
24%
Quality Control
6%
Ristocetin
11%
Sample
56%
Thrombocyte Aggregation
5%
Thrombocyte Function
7%
Thrombocytopenia
8%
Thrombophilia
5%
Thrombotic Thrombocytopenic Purpura
6%
Time
18%
Von Willebrand Disease
65%
Von Willebrand Factor
100%
Von Willebrand Factor
11%
Pharmacology, Toxicology and Pharmaceutical Science
Antibody
9%
Anticoagulant Agent
35%
Antivitamin K
8%
Apixaban
7%
Biological Product
5%
Bleeding
9%
Blood Clotting Factor
7%
Cardiovascular Disease
6%
Dabigatran
8%
Direct Oral Anticoagulant
18%
Diseases
10%
Drug
13%
Hemophilia
5%
Hemostatic Agent
5%
Heparin
27%
Heparin Induced Thrombocytopenia
16%
Lupus Anticoagulant
17%
Prothrombin
6%
Reagent
6%
Rivaroxaban
11%
Thrombin
8%
Thrombocyte Factor 4
9%
Thromboplastin
6%
Thrombosis
26%
Thrombotic Thrombocytopenic Purpura
10%
Vaccine
13%
Vein Thrombosis
8%
Venous Thromboembolism
14%
Von Willebrand Disease
5%
Von Willebrand Factor
5%
Warfarin
5%
